Brief: TRACON Expects Current Cash And Cash Equivalents Will Fund Operations Into 2023
11/05/2022 21:50
May 11 (Reuters) - TRACON Pharmaceuticals Inc TCON.O :
* TRACON PHARMACEUTICALS REPORTS FIRST QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
* TRACON PHARMACEUTICALS INC - EXPECTS THAT ITS CURRENT CASH
AND
CASH EQUIVALENTS WILL FUND OPERATIONS INTO 2023
* TRACON PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.48
Source text for Eikon: ID:nGNX2mHKdm
Further company coverage: TCON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TRACON Pharmaceuticals
See all newsBrief: TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In March: Earnings Summary
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Tracon Pharmaceuticals Inc Expected To Post A Loss Of $1.19 A Share: Earnings Preview
Brief: Tracon Pharmaceuticals Files For Offering Of Common Stock, Pre-Funded Warrants